Posters

      Quantitative Adverse Outcome Pathway: A New Prediction Tool to Assess Human Risk of Decreased Lung Function When Switching from Combustible Cigarettes to Heated Tobacco Products

      Mathis, C.; Sewer, A.; Calvino, F.; Luettich, K.; Iskandar, A.; Talikka, M.

      Conference date
      Sep 25, 2023
      Conference name
      6th Scientific Summit on Tobacco Harm Reduction: Novel producs, Research & Policy 2023
      Topic
      Summary

      Adverse outcome pathways (AOPs) are simple linear or branching paths representing a sequence of molecular, cellular, tissue, and organ level perturbations (or “key events”). They are triggered by the interaction between a particular compound and a cellular component (identified as the “molecular initiating event”) that precedes an adverse outcome (AO) at the organism or population level. AOPs integrate data from alternative test methods in line with the “3R” paradigm (to refine, reduce, and replace laboratory animals) and serve the development of new predictive tools for hazard assessment.

      Here, we took advantage of the AOP 411 that describes how increased oxidative stress, reduced ciliary beat frequency (CBF), and reduced mucociliary clearance (MCC) sequentially lead to decreased lung function to develop mathematical models reflecting the relationships between key events and allowing the quantification of AO prediction. As a case study, we evaluated the potential risk of impaired lung function associated with tobacco heating system (THS) use compared with cigarette smoking, by using data from a series of in vitro studies on the THS, employing advanced human tissue culture models, and by mapping them in the AOP 411. Our new quantitative AOP (qAOP) predicted a 48.7% reduced risk of decreased CBF based on measurement of oxidative stress indicators and 18.4% reduced risk of decreased MCC based on measurement of CBF in THS aerosol compared with cigarette smoke-exposed cultures.

      Finally, modeling based on human MCC data predicted a 79.3% reduced risk of decreased lung function in heated tobacco product switchers compared with smokers. In summary, the development and use of this new qAOP may be a potent alternative to evaluate the risk of decreased lung function in the context of tobacco harm reduction while waiting for long-term clinical studies and epidemiological data.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.